A high proportion of populations in most developing countries live below the poverty line, and those near refuse grounds resort to dumpsite farming to grow food. Consequently, high levels of waste-derived contaminants are found in crops consumed by these people. This study investigates the extent to which crops cultivated on the Mbale dumpsite (Uganda) were contaminated by 11 metals and 2 non-metals: iron (Fe), aluminium (Al), zinc (Zn), manganese (Mn), copper (Cu), mercury (Hg), lead (Pb), nickel (Ni), cobalt (Co), cadmium (Cd), selenium (Se), chromium (Cr), and arsenic (As). We investigated how element bioaccumulation in crops was influenced by the growth period (short-term and long-term crop maturity). The short-term crops were Zea mays and Amaranthus cruentus whereas the long-term crops were Manihot esculenta, Colocasia esculenta, Musa acuminata, Carica papaya, Coffea arabica and Saccharum officinarum.
Results showed that nine metals were present at concentrations above WHO/FAO food safety recommendations and hence may pose health risks to consumers. In this study, leaves contained higher metal concentrations than other analysed consumable parts. Pb and Co were found at higher concentrations in leaves of short-term, than in long-term crops. Among short-term crops, only Zea mays grains/seeds contained permissible metal concentrations by WHO/FAO standards.
The growth period was also found to influence metal bioaccumulation in crop types. Pb, Co, Fe, Al, and Cu concentrations were significantly higher in the short-term than in long-term crops while Mn, Ni and Cr concentrations were higher in long-term than in short-term crops. Overall, public awareness about health risks associated with consuming short-term leafy crops grown on dumpsites should be escalated to reduce toxic metal exposure. While implementing such a campaign, the food supply of individuals whose survival depends on https://biodas.org/ such crops should not be jeopardized. Therefore, farmers need alternative farming areas outside dumpsites.
An experimental study to evaluate the effect of Nitya Sevaniya (daily consumable) and Nitya Asevaniya (daily non-consumable) food items on albino rats
Background: As per Ayurveda, Nitya Sevaniya (NS) food items are recommended for daily intake while Nitya Asevaniya (NAS) food items should be avoided for daily intake due to their systemic wholesome and unwholesome effects after consumption, respectively.
Aim and objectives: The present study was conducted to perform in vivo safety evaluation of selected Nitya Sevaniya and Nitya Asevaniya food items.
Materials and methods: Thirty rats were randomly divided into five groups-each containing six Charle’s Foster strain albino rats. Group 1 served as standard diet group, groups 2 and 3 served as test drug received groups namely NS50 and NS100, in which 50% and 100% mixture of Nitya Sevaniya food was administered, respectively. Group 4 and 5 as test drug received groups Nitya Asevaniya 50 (NAS50) and Nitya Asevaniya 100 (NAS100), in which 50% and 100% Nitya Asevaniya food mixtures was administered, respectively. The test diet was administered orally in the form of freshly prepared pellet twice a day ad libitum for 90 days. Parameters studied were gross behavior, body and organ weight, food and water intake, fecal and urine output, hematological and biochemical parameters, electrocardiogram and histology of various organs.
Results: In the NAS100 group, a significant change was observed in 20 of 47 parameters in view of pathological aspect. Among them, three parameters, i.e., platelet count, serum glutamic-oxaloacetic transaminase (SGOT) and indirect bilirubin were above normal limits, while other parameters were within the normal limits. No significant change was observed in any of the parameters in the NS50 and NS100 group after 90 days of administration as compared with the control group.
Conclusion: Considering findings of this study, it is concluded that selected NS food items are safe while consumption of only selected Nitya Asevaniya food items (when administered in 100% dose) for 90 days have the potential of inflammatory changes in the liver, spleen; fat deposition in kidney and impairment of cardiac and renal functions.
Competitive Revenue Strategies in the Medical Consumables Industry: Evidence from Human Resources, Research and Development Expenses and Industry Life Cycle
- This study attempted to explore the competitive advantage strategies of the medical consumables industry (MCI) from the perspectives of human resources, research and development (R&D) and the industry life cycle. As one of the essential branches of modern medical device industry, the MCI has developed rapidly in recent years as global demand for medical consumables has shown continual growth, but it also faces market uncertainty.
- This study took Taiwan’s small/medium medical consumables enterprises (SMMCEs) as a sample, and used the translog revenue function to study the competitive advantage of the MCI through human resource and R&D investment strategies and the stage characteristics of the industry life cycle curve. The results showed that the various human resources and R&D expenses of the small/medium medical consumables industry (SMMCI) can interact with each other to influence total revenue and that the SMMCI needs more varied types of human resources to enhance its competitive advantage.
- The total revenue of the SMMCI decreased as education inputs rose, but it increased along with increases in the number of employee and R&D inputs. Observed from the life cycle curve of the SMMCI, total revenue increased rapidly during the startup and growth stages, increased slowly during the maturity stage, and decreased during the decline stage. Finally, we put forward competitive advantage strategies and management suggestions for medical consumables enterprises (MCEs). We are the first to document the life cycle curve and competitive advantage strategies of the MCI, thereby contributing to the related literature.
[Development of Intelligent Management System for High Value Consumable Material in Operating Room]
Operation room is the most important link for carrying out medical activities in hospital whose demand for medical consumable material is also very large. With the increase of types of consumable material, the process of consumable material management in operating room becomes more complicated, and the traditional management mode can not meet the needs.
In this paper, the technology of Internet of things and artificial intelligence is used to design an intelligent management system of high value consumable material in operating room which improves the efficiency of operation of high value consumable material in operating room, reduces the cost of manpower and improves the safety.
Equipment Genezap Solution |
|||
| 2137A | Unibiotest | 250 mL | 150 EUR |
Equipment Genezap Solution |
|||
| 2137B | Unibiotest | 1L | 400 EUR |
Equipment Genezap Solution |
|||
| 2137C | Unibiotest | 5L | 1200 EUR |
Inspection Equipment Nucleofector II |
|||
| LOAXP-1001 | Westburg | each | 411.9 EUR |
BioWand™ Personal UV Sterilizer, for surfaces and equipment, 1 ea |
|||
| U1001-W | MTC Bio | 1/pack | 69 EUR |
Inspection Equipment 96-well Shuttle |
|||
| LOAXP-1002 | Westburg | each | 819.25 EUR |
Inspection equipment 4D Single Cuvette |
|||
| LOAXP-1003 | Westburg | each | 937.07 EUR |
Inspection equipment 4D 16-well strip |
|||
| LOAXP-1004 | Westburg | each | 954.57 EUR |
SLIDE-A-LYZER DIALYSIS CASSETTE Lab Equipment |
|||
| GWB-Q00430 | GenWay Biotech | 1 UNITS | Ask for price |
genesig lab in a box - DNA/RNA extraction equipment |
|||
| Z-genesigEASY-LIAB | Novacyt Group | n/a | 824 EUR |
Bracket and Long Tag BE Modernotecnica Consumables |
|||
| STAFSL | BRADY NV | Pack of 192 Piece(s) | 55.45 EUR |
Glove Bag Evaluation Kit, 20" x 20" x 12", side equipment opening. One Glove Bag |
|||
| 108DS-20-20H-EVAL | Glascol | each | 76 EUR |
Glove Bag Evaluation Kit, 30" x 20" x 14", side equipment opening. One Glove Bag |
|||
| 108DS-30-20H-EVAL | Glascol | each | 97 EUR |
Glove Bag Evaluation Kit, 17" x 17" x 11", front equipment opening. One Glove Bag. |
|||
| 108DX-17-17H-EVAL | Glascol | each | 79 EUR |
Glove Bag Evaluation Kit, 27" x 17" x 12", front equipment opening. One Glove Bag. |
|||
| 108DX-27-17H-EVAL | Glascol | each | 79 EUR |
Glove Bag Evaluation Kit, 27" x 27" x 15", front equipment opening. One Glove Bag. |
|||
| 108DX-27-27H-EVAL | Glascol | each | 88 EUR |
Glove Bag Evaluation Kit, 37" x 27" x 18", front equipment opening. One Glove Bag. |
|||
| 108DX-37-27H-EVAL | Glascol | each | 97 EUR |
Glove Bag Evaluation Kit, 37" x 37" x 25", front equipment opening. One Glove Bag. |
|||
| 108DX-37-37H-EVAL | Glascol | each | 97 EUR |
Glove Bag, inflatable glove chamber, 20" x 20" x 12", side equipment opening. Box of 3. |
|||
| 108DS-20-20H-3 | Glascol | each | 163 EUR |
Glove Bag, inflatable glove chamber, 20" x 20" x 12", side equipment opening. Box of 6. |
|||
| 108DS-20-20H-6 | Glascol | each | 242 EUR |
Glove Bag, inflatable glove chamber, 30" x 20" x 14", side equipment opening. Box of 3. |
|||
| 108DS-30-20H-3 | Glascol | each | 228 EUR |
Glove Bag, inflatable glove chamber, 30" x 20" x 14", side equipment opening. Box of 6. |
|||
| 108DS-30-20H-6 | Glascol | each | 338 EUR |
Glove Bag, inflatable glove chamber, 17" x 17" x 11", front equipment opening. Box of 6 |
|||
| 108DX-17-17H | Glascol | each | 207 EUR |
Glove Bag, inflatable glove chamber,27" x 17" x 12", front equipment opening. Box of 6 |
|||
| 108DX-27-17H | Glascol | each | 299 EUR |
Be First to Comment